REDWOOD CITY, Calif.,
Oct. 15, 2018 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for use in a medically
supervised setting, today announced a poster presentation at the
American Society of Anesthesiologists (ASA) in San Francisco highlighting sublingual
sufentanil. The poster presentation will include efficacy and
integrated safety results of sufentanil sublingual tablets across
surgery types.
Included in this presentation are results from two randomized
and placebo-controlled studies in post-operative patients following
bunionectomy (SAP202) and abdominal surgery (SAP301). Two studies
were open-label and single-arm intended to evaluate sufentanil
sublingual tablet 30 mcg (DSUVIA™) in the emergency department
(SAP302) and in older, post-operative patients, many with
comorbidities (SAP303). Statistically significant SPID12
differences were observed in favor of DSUVIA compared to placebo.
Nausea was the most commonly reported AE across all surgery
subgroups.
"Pain is the most common reason for delayed discharge from
outpatient surgery centers and the main reason for unanticipated
hospital admissions," said Dr. Jacob
Hutchins, Associate Professor at the University of Minnesota Medical Center. "Inadequate
management of pain in the perioperative period causes unnecessary
suffering and discomfort, and these results show that DSUVIA could
offer potential analgesic advantages in patients requiring
non-invasive, acute pain management."
The data will be presented at the American Society of
Anesthesiologists ANESTHESIOLOGY® 2018 Annual Meeting, October 13-17 in San
Francisco, California.
Details on the Poster Presentation is as follows:
Title: Efficacy and Integrated Safety Results of the
Sufentanil Sublingual Tablet 30 mcg by Procedure Type for
Management of Moderate to Severe Acute Pain
Date &
Time: Tuesday, October 16, 2018;
12:00-12:30pm PT
Location: Moscone Center, North Hall D, Area B, Monitor 6
Presenters: Jacob Hutchins, MD,
MHA
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's proprietary,
non-invasive sublingual formulation technology delivers sufentanil
with consistent pharmacokinetic profiles. The company has two
product candidates in the United
States including DSUVIA™ (sufentanil sublingual tablet, 30
mcg), with a proposed indication for the treatment of
moderate-to-severe acute pain in medically supervised settings, and
Zalviso® (sufentanil sublingual tablet system, 15 mcg) being
developed as an innovatively designed patient-controlled analgesia
(PCA) system for reduction of moderate-to-severe acute pain in
hospitalized patients. DZUVEO™, as DSUVIA is known in Europe, and Zalviso are both approved products
in Europe.
For additional information about AcelRx, please visit
www.acelrx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dsuvia-efficacy-and-safety-data-to-be-presented-at-the-american-society-of-anesthesiologists-asa-annual-conference-300730818.html
SOURCE AcelRx Pharmaceuticals, Inc.